ixekizumab
eli lilly
['ixekizumab', 'axspa']
#spa #posters #acr22 0403. efficacy and safety of ixekizumab in chinese patients with r-axspa: 16-week results from a phase 3 study asas40 response rate was significantly higher in the ixe80q4w group than placebo (40.9% vs. 7.8%, p&lt; 0.001) at week 16 #acrambassador
Rheumatologist | Epi | ASAS | Twitter Ambassador (ACR/ ARD-BMJ) | ArLAR ARCH President | St Joseph University & HDF Beirut | Love Music | Travel Books